The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Medically reviewed by Marla Anderson, MD Stomach cancer—or gastric cancer—occurs when cells in the lining of the stomach wall ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Exelixis has won U.S. Food and Drug Administration expanded approval of its Cabometyx cancer drug for certain patients with advanced neuroendocrine tumors.

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...

The approval for use in advanced neuroendocrine tumors is supported by data from the phase 3 CABINET trial (ClinicalTrials.gov Identifier: NCT03375320). The double-blind, placebo-controlled study ...